Glaukos Corporation (GKOS)
Free
No email, no account, no signup.
Pulling latest news for Glaukos Corporation…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NYSE
Type
Biotech
Sector
Ophthalmic medical technology and pharmaceuticals
Market Cap
$7.3B
We're already tracking Glaukos Corporation — here are the latest events we've registered
Recent News
- On April 29, 2026, Glaukos reported first-quarter revenue of $150.6 million and raised its full-year sales guidance to $620–$635 million. In June 2026, institutional filings showed that Norges Bank and Goldman Sachs significantly increased their stakes in the company. These updates reflect the company's ongoing commercial expansion of its iDose TR and corneal health franchises.
Want to know how this news affects Glaukos Corporation? Order the analysis.
Order analysis – What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Glaukos Corporation will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.